# Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes

> **NCT00434850** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 14 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **BIOLOGICAL:** Allogeneic Pancreatic Islet Cells
- **DRUG:** Deoxyspergualin
- **BIOLOGICAL:** Antithymocyte globulin
- **BIOLOGICAL:** Daclizumab or basiliximab
- **DRUG:** Sirolimus
- **DRUG:** Tacrolimus
- **BIOLOGICAL:** Etanercept

## Key facts

- **NCT ID:** NCT00434850
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2011-09
- **Final completion:** 2013-11
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2016-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00434850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00434850, "Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00434850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*